Guessing the future price of the next major breakthrough in prostate cancer treatment

In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …

“Normal” sexual functionality after a radical prostatectomy — it’s not very likely

According to a report on the Science Daily web site today, a presentation at the ongoing European Association of Urology (EAU) meeting in Madrid, Spain, suggests that the ability to regain normal erectile and sexual function after a radical prostatectomy is actually rather worse than one might have thought. … READ MORE …

Time to prove a treatment-related prostate cancer survival benefit

For most of the past 20 years it has generally been considered that it took 10 years to show that a new form of therapy was effective and safe in the treatment of localized prostate cancer. We may need to seriously re-assess that time period. … READ MORE …

Patient life expectancy and application of radical prostatectomy in Ontario, Canada

An interesting epidemiological study just published on line in the Journal of Urology suggests that urologic surgeons in Ontario, Canada, are rather good at at estimating which patients diagnosed with prostate cancer have a life expectancy of 10+ years, making them reasonable candidates for radical prostatectomy. … READ MORE …

Of cost, quality, and care for low-risk prostate cancer

A newly published study in the Annals of Internal Medicine has offered an analysis of the cost-effectiveness of “observation” as compared to immediate initial treatment for men diagnosed with low-risk, localized prostate cancer. … READ MORE …

Life expectancy ≤ 10 years and the risks associated with treatment

According to Reuters, a new article, forthcoming on line in the Annals of Internal Medicine, tells us (not too surprisingly) that, “Older men with other illnesses may not live long enough to benefit from aggressive prostate cancer treatments, such as prostate removal or radiation, and they’d have to live with their side effects.” … READ MORE …

“There’s more to life than death”

We strongly recommend to all our readers a commentary in this week’s New England Journal of Medicine by Drs. Pamela Hartzband and Jerome Groopman. It deals forcefully with distinction between “statistical proof” of the lack of value of PSA testing and the accuracy of that statistical proof as a basis for clinical decision-making. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,367 other followers